Technology company !%Bioptigen Inc.%! of Durham, N.C., has received clearance from Health Canada to begin marketing its handheld ophthalmic imaging systems for patient use. The Envisu series spectral domain ophthalmic imaging system uses low-power near-infrared light to produce high-resolution depth-resolved images of eye structures in real time. Based on OCT technology, the systems are expected to enable greater understanding of eye disease progression, detection and treatment. “Now that Bioptigen has regulatory approval to market our technology in Canada and the European Union, adults and children can begin benefiting from this flexible and detailed imaging platform that complements existing diagnostic techniques and treatments,” said Eric Buckland, president and CEO.